Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nurix Therapeutics Receives FDA Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia Treatment Quiver Quantitative, Inc. - Thu Dec 19, 4:20PM CST

Nurix Therapeutics announces FDA Fast Track designation for NX-5948, a drug targeting Waldenstrom’s macroglobulinemia.Quiver AI SummaryNurix Therapeutics, Inc. announced that the FDA has granted Fast...

NRIX : 19.93 (+1.84%)
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia GlobeNewswire - Thu Dec 19, 6:00AM CST

NRIX : 19.93 (+1.84%)
Nurix Therapeutics Reports Promising Phase 1a/1b Clinical Trial Results for NX-5948 in Relapsed or Refractory CLL/SLL at ASH Annual Meeting Quiver Quantitative, Inc. - Tue Dec 10, 3:14AM CST

Nurix Therapeutics reports promising NX-5948 trial results for CLL/SLL, highlighting response rates and safety profile. Webcast scheduled for updates.Quiver AI SummaryNurix Therapeutics, Inc. has reported...

NRIX : 19.93 (+1.84%)
Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting GlobeNewswire - Mon Dec 9, 5:00PM CST

NRIX : 19.93 (+1.84%)
Nurix Therapeutics to Host Webcast on Phase 1a/1b Trial Data for NX-5948 on December 9, 2024 Quiver Quantitative, Inc. - Mon Dec 2, 4:16PM CST

Nurix Therapeutics to present NX-5948 clinical trial data in a webcast on December 9, 2024, featuring guest speaker Dr. Nirav N. Shah.Quiver AI SummaryNurix Therapeutics, Inc. announced a live webcast...

NRIX : 19.93 (+1.84%)
Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Mon Dec 2, 6:00AM CST

NRIX : 19.93 (+1.84%)
Nurix Therapeutics to Present Corporate Update at Piper Sandler Healthcare Conference on December 3, 2024 Quiver Quantitative, Inc. - Mon Nov 25, 4:16PM CST

Nurix Therapeutics will present updates on its drug development at the Piper Sandler Healthcare Conference on December 3, 2024.Quiver AI SummaryNurix Therapeutics, Inc. announced that its president and...

NRIX : 19.93 (+1.84%)
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference GlobeNewswire - Mon Nov 25, 6:00AM CST

NRIX : 19.93 (+1.84%)
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia GlobeNewswire - Wed Nov 20, 3:00PM CST

NRIX : 19.93 (+1.84%)
Nurix Therapeutics Presents Preclinical Data on NX-5948 and GS-6791 at ACR Convergence 2024 Quiver Quantitative, Inc. - Sun Nov 17, 7:44PM CST

Nurix Therapeutics presented preclinical data on NX-5948 and GS-6791 at ACR Convergence 2024, highlighting their potential in treating inflammatory diseases.Quiver AI SummaryNurix Therapeutics, Inc. has...

NRIX : 19.93 (+1.84%)

Barchart Exclusives

Bearish on the Market? 2 Defensive Stocks for Maximum Portfolio Protection. Barchart - 1 hour ago
As economic growth is anticipated to slow, UBS highlights these two dividend-paying defensive stocks as smart picks, shifting focus away from cyclical stocks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot